Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 5,467 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Solid Tumor Malignancies, Cancer Clear all

Conditions: Advanced Solid Cancers, Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Interventions: Zalifrelimab; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 11
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Cancer
Interventions: GSK1120212, Docetaxel + GSK1120212, Erlotinib + GSK1120212, Pemetrexed + GSK1120212, Carboplatin + GSK1120212, Nab-paclitaxel + GSK1120212, Gemcitabine + GSK1120212, Everolimus + GSK1120212; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 13
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Sacramento, California + 10 more

Conditions: Solid Tumors
Interventions: INCB161734, Placebo, Investigator's choice of chemotherapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 69
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 55 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: vorinostat, paclitaxel, carboplatin, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: irinotecan hydrochloride, raltitrexed; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions: filgrastim, docetaxel, gemcitabine hydrochloride; Biological · Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Solid Tumors
Interventions: PLX3397, Paclitaxel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 8
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 5 more

Conditions: Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Malignant Digestive System Neoplasm, Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Minimal Residual Disease
Interventions: Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE; Biological
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm, Post-Transplant Lymphoproliferative Disorder
Interventions: Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine, QS21; Procedure · Drug · Biological
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
Interventions: ANV419; Drug
Lead sponsor: Anaveon AG; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 6 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Survey Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumors
Interventions: WGI-0301; Drug
Lead sponsor: Zhejiang Haichang Biotech Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Whittier, California • Baltimore, Maryland

Conditions: Advanced Solid Tumor, BRAF V600 Mutation
Interventions: ABM-1310, Cobimetinib; Drug
Lead sponsor: ABM Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: San Francisco, California • Stanford, California • Miami, Florida + 4 more

Conditions: Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions: Taxotere (Docetaxel), Alimta (Pemetrexed); Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Advanced Solid Tumors, Multiple Myeloma
Interventions: ONC-201; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Malignant Solid Neoplasm, Caregiver, Metastatic Malignant Solid Neoplasm, Recurrent Leukemia, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Plasma Cell Myeloma
Interventions: Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
Interventions: RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed; Drug
Lead sponsor: Inspirna, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 21
States / cities: Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 16 more

Conditions: Lung Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer
Interventions: 2-deoxy-D-glucose (2DG); Drug
Lead sponsor: Threshold Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 3
States / cities: Miami, Florida • Indianapolis, Indiana • San Antonio, Texas

Conditions: Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma
Interventions: MGC028; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: San Francisco, California • Boston, Massachusetts • Grand Rapids, Michigan + 3 more

Conditions: Solid Tumours
Interventions: Savolitinib, Famotidine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem, Piperacillin-Tazobactam, Vancomycin, Daptomycin, Linezolid; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: TY-2136b; Drug
Lead sponsor: TYK Medicines, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Providence, Rhode Island • Houston, Texas

Conditions: Solid Cancers
Interventions: GDC-0917; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Nashville, Tennessee • San Antonio, Texas

Conditions: Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Avelumab, Berzosertib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

GSK1120212 Rollover Study

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors

Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

Evaluation of Satisfaction With Quality of Care on the Palliative Care Unit

A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors

A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors

A Study of MGC028 in Participants With Advanced Solid Tumors

A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors